INTRODUCTION
============

As the most common primary (70% to 90%) liver cancer, hepatocellular carcinoma (HCC) is the fifth most frequent malignancy and the second leading cause of cancer-related mortality all over the world.[@b1-gnl-13-669] Annually, approximately seven million new cases of HCC were diagnosed and almost an equal number of deaths occurred.[@b1-gnl-13-669] With the high prevalence of hepatitis B virus (HBV) infection, more than 50% of the total number of new cases and deaths occurred in China.[@b1-gnl-13-669] Since the limited availability of donor organs and expensive medical cost make liver transplantation problematic, liver resection is still considered to be the first-line option for the patients with early stage HCC.[@b2-gnl-13-669]--[@b4-gnl-13-669] Moreover, increasing evidence has confirmed that the patients with intermediate stage HCC or even advanced HCC with portal vein tumor thrombosis limited to the first-order branch could also achieve survival benefit from liver resection.[@b5-gnl-13-669],[@b6-gnl-13-669] However, the long-term survival of HCC remains unsatisfactory owing to the extremely high postoperative recurrence rate.[@b7-gnl-13-669],[@b8-gnl-13-669]

Microvascular invasion (MVI) is defined as the presence of tumor emboli in the hepatic veins, portal system, and/or lymphatic ducts on microscopy.[@b9-gnl-13-669] The incidence of MVI ranged from 15.0% to 57.1% in previous studies.[@b9-gnl-13-669] The detection rate of MVI was closely correlated with the tumor size and numbers.[@b10-gnl-13-669] The presence of MVI has been widely recognized as a poor prognostic factor for patients who undergo curative liver resection.[@b9-gnl-13-669],[@b11-gnl-13-669]--[@b14-gnl-13-669] And for the patients with MVI, deeper vascular-wall invasion, more invaded vessels and further distance of invasion indicated worse prognostic outcomes.[@b10-gnl-13-669],[@b15-gnl-13-669]

In recent years, many studies have identified multiple clinical variables associated with MVI, and some investigators even established accurate models for predicting MVI based on preoperative parameters.[@b11-gnl-13-669],[@b12-gnl-13-669],[@b16-gnl-13-669] These studies were meaningful to guide the surgeons to choose reasonable treatments and expand the resection margin, owing to the fact that more than 90% MVI occurred in the area where was less than 1 cm from the tumor edge.[@b10-gnl-13-669] However, to the best of our knowledge, studies have seldomly specifically focused on the prognosis of the patients who were histologically diagnosed with MVI after surgery so far. And the independent risk factors which were associated with the recurrence and long-term survival of this subset of patients remain unclear. Furthermore, as MVI itself is an established risk factor, it is uncertain whether conventional staging systems of HCC were appropriate for this special group patients or not. Therefore, an effective prediction model is imperative to plan personalized surveillance strategies and adjuvant therapies after surgery for this subset of patients. Nomogram has been regarded as a reliable tool to integrate and quantify important risk factors for oncologic prognosis.[@b17-gnl-13-669]--[@b19-gnl-13-669] And its superiority could be estimated by comparing the concordance index (C-index) with other staging systems. Using this easy-to-use predicting model, it is convenient to calculate the unique risk scores and an individual survival possibility for each patient. The aim of this study was to generate novel nomograms for the prognostic prediction of HCC patients with MVI after curative hepatectomy.

MATERIALS AND METHODS
=====================

1. Patients
-----------

Patients who underwent curative hepatic resection for HCC between January 2009 and May 2015 at West China Hospital were retrospectively reviewed in this study. The following are criteria for the inclusion: (1) pathologically diagnosed as HCC with MVI (2) Child-Pugh A or B liver function; (3) no evidence of extrahepatic metastasis; (4) treated by curative resection, which was defined as no residual tumor and a negative resection (R0) margin based on the histological examination. The exclusion criteria were (1) combined with cholangiocarcinoma or other malignancy; (2) the gross vascular invasion (GVI) located in the main trunk or contralateral branch of portal vein; (3) received other preoperative anticancer treatments; (4) without complete clinical or follow-up data. This study was approved by the Clinical Research Ethics Committee of West China Hospital (IRB number: FWA00009482IRBIORG0004190), and owing to the type of study, formal consents were unnecessary.

2. Diagnosis and surgery
------------------------

Before surgery, each candidate for liver resection had to undergo routine blood tests, conventional coagulation tests, liver and renal function tests, HBV/HCV screening tests, HBV deoxyribonucleic acid (HBV-DNA) measurements, and the examination of serum tumor markers including alpha-fetal protein (AFP), carcinoembryonic antigen, carbohydrate antigen 19--9 (CA19-9) and CA-125. Electrocardiogram and chest radiography were performed routinely, pulmonary function test and echocardiography were regularly carried out for patients with age more than 65 years old or when clinically necessary. Three-phase-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) scans were performed to preliminarily evaluate the characteristics of the tumors and plan surgery strategy.

The surgical procedures were determined preoperatively based on tumor status, liver function, possibility of adequate surgical margin and technical difficulty in liver resection. Anatomic resection was the preferred option for each patient. During surgery, intraoperative ultrasonography was regularly applied to guide the resection margin and identify additional nodules missed by preoperative imaging.[@b20-gnl-13-669],[@b21-gnl-13-669] The two most commonly used methods for parenchymal dissection were Cavitron Ultrasonic Surgical Aspirator and clamp crushing. We employed hemihepatic vascular inflow occlusion or the intermittent Pringle's maneuver to control surgical blood loss. Anesthesia was maintained by reducing the tidal volume of ventilation to 30% to 40% of the standard volume and keeping the central venous pressure below 5 cm H~2~O to decrease the amount of blood loss from the hepatic veins during hepatectomy.

3. Pathological examination
---------------------------

The resected specimens were embedded in paraffin and delivered to histological department for histological examination. The differentiation grade was confirmed based on the criteria of the Edmondson-Steiner classification.[@b22-gnl-13-669] Satellite lesions were defined as separate nodules within 2 cm both in size and distance from primary tumor.[@b15-gnl-13-669],[@b23-gnl-13-669] The diagnosis of MVI was based on "the evidence-based practice guidelines for standardized pathological diagnosis of primary liver cancer in China: 2015 update,"[@b23-gnl-13-669] which was commonly used in clinical practice in China and cited by multiple previous literatures.[@b10-gnl-13-669],[@b24-gnl-13-669] The histological diagnosis of each patient was performed by two professional pathologists; any disagreement was resolved by a group discussion.

4. Follow-up
------------

After discharge, all patients were regularly followed up at the first postoperative month and then at 3-month intervals in the first 3 years and every 6 months thereafter. Laboratory examinations including routine blood tests, liver function tests, AFP and HBV-DNA load, abdominal ultrasonography, and chest X-ray were generally carried out. Enhanced abdominal CT/MRI was performed when suspicious lesions were found or AFP showed persistent elevation. Bone scintigraphy was applied to confirm the bone metastases. For patients with HBV-DNA level more than 10^3^ copies/mL, the usage of antiviral drugs with a low rate of resistance (e.g., entecavir or tenofovir disoproxil) were monitored.[@b25-gnl-13-669] Once the recurrence was confirmed, appropriate therapies including liver resection, radiofrequency ablation (RFA), liver transplantation, transarterial chemoembolization (TACE), sorafenib and/or best care protocol were recommended accordingly. The endpoints of this study were the 1, 2 and 3-year disease-free survival (DFS) and overall survival (OS) rate. We defined the DFS as the interval between the date of liver resection and the date of confirmation of recurrence. The OS was the interval between the date of surgery and the date of death or the last follow-up.

5. Statistical analysis
-----------------------

All statistical analyses were conducted using SPSS version 21.0 (IBM Corp., Armonk, NY, USA), Prism version 5.0 (GraphPad Software, San Jose, CA, USA), and R software version 3.5.0 with the rms package (The R Foundation, Vienna, Austria; <http://www.r-project.org/>). Categorical variables were expressed as count or percent and compared using the chi-square or Fisher exact test as appropriate. Continuous data were reported as mean±standard deviation and were compared using the Student t-test, one-way analysis of variance or Mann-Whitney test as appropriate. The survival curves were plotted using the Kaplan-Meier method and compared using the log-rank test. All included patients were randomly divided into training and validation cohorts in the ratio of 2 to 1, which were used to construct and validate the nomograms respectively. Univariate analysis was carried out to investigate potential risk factors, then the factors with a p-value less than 0.05 in the univariate analysis were entered into stepwise multivariate analysis using Cox model to identify independent risk factors of the DFS and OS, respectively. The establishment of nomograms was based on the results of independent risk factors derived from multivariate analysis in training cohort. The predictive accuracy of nomograms was evaluated by the Harrell's C-index; a bootstrap with 1,000 resamples was performed to reduce biased estimate. A larger C-index value represents more accurate prediction. The differences of the C-index between the nomogram and other staging systems were analyzed using the rcorrp.cens package in R.[@b19-gnl-13-669] The calibration curves were applied to illustrate the agreement between the nomogram-predicted and actual observed Kaplan-Meier estimates for survival probability. External validations of nomograms were carried out in validation cohort using the same methods. The discrimination ability of nomograms was estimated by stratifying the prognostic outcomes of patients using the risk scores generated from the nomograms. All statistical tests were two-tailed, p-value less than 0.05 was considered statistically significant.

RESULTS
=======

1. Clinical characteristics and prognostic outcomes of all included patients
----------------------------------------------------------------------------

From January 1, 2009 to May 31, 2015, a total of 385 consecutive patients met our eligible criteria were enrolled in this study. Then 255 and 130 patients were randomly assigned to the training and validation cohorts, respectively. The detailed clinicopathological information of patients in different cohorts are listed in [Table 1](#t1-gnl-13-669){ref-type="table"}. In brief, most patients were male (male/female: 339/46), the average age of patients was 50.1±12.5 years ranging from 16 to 80 years. The hepatitis B surface antigen (HBsAg) was detected in 342 patients (88.83%), and 71 patients (20.0%) were hepatitis B e antigen (HBeAg) positive. One hundred seventy-eight patients (46.23%) had HBV-DNA load more than 10^3^ copies/mL, and 56 out of 178 (31.46%) were treatment-naïve patients to whom entecavir or tenofovir disoproxil were added before surgery. During follow-up, the usage of antiviral drugs was seriously monitored and the HBV-DNA load was regularly detected for patients with aberrant HBV-DNA load. AFP levels were significantly elevated in 226 patients (57.66%, ≥400 ng/mL). The preoperative image findings showed that the average diameter of largest tumor was 8.0 cm (range, 1.8 to 20 cm), multiple nodules were identified in 101 patients (26.23%), and 129 patients (33.51%) had GVI which was defined as the tumor embolus being observed in the first or second branches of the portal veins by preoperative imaging. With respect to the histological results, more than half of the patients (54.81%) had poor grade of tumor differentiation. Liver cirrhosis were verified in 168 patients (43.64%) with the Ishak score of 6. The Glisson's capsule invasion which was defined as the tumor cells invading but not penetrating the liver capsule was found in 107 patients (27.29%), 79 patients (20.52%) had satellite lesions and 14 patients (3.64%) had positive hepatic lymph node metastasis. The follow-up was censored in May 31, 2018 with a median follow-up period of 17 months ranging from 1 to 111 months. During the follow-up period, the majority of the patients (333/385, 86.49%) experienced tumor recurrence, and recurrence occurred in 71.7% within the first postoperative year. Among them, 18 patients (4.67%) underwent rehepatectomy, 14 (3.63%) underwent RFA, five patients (1.30%) received salvage liver transplantation, and 160 patients (41.56%) underwent TACE. The median number of TACE was 1 with a range from 1 to 10. The patients had a median DFS of 5 months with DFS rates of 1-year: 29.3%, 2-year: 20.6%, 3-year: 16.6% ([Fig. 1A](#f1-gnl-13-669){ref-type="fig"}), and a median OS time of 17 months with OS rates of 1-year: 58.7%, 2-year: 39.8%, 3-year: 34.4% ([Fig. 1B](#f1-gnl-13-669){ref-type="fig"}).

2. Independent risk factors of DFS and OS in training cohort
------------------------------------------------------------

The results of univariate and multivariate analyses for the DFS and OS in the training cohort are presented in [Table 2](#t2-gnl-13-669){ref-type="table"}. The univariate analysis revealed that 12 clinical variables including age, HBV-DNA load, AFP level, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), gamma-glutamyl transpeptidase, tumor size, tumor number, GVI, differentiation, Glisson's capsule invasion and satellite lesions were significantly associated with both the DFS and OS. Meanwhile, we also found that neutrophil, aspartate aminotransferase and intraoperative blood loss were additional risk factors for the OS. These variables were integrated into stepwise multivariate analyses to identify independent risk factors of the DFS and OS. The results showed that five factors including age (DFS: hazard ratio \[HR\], 0.98; 95% confidence interval \[CI\], 0.97 to 0.99; p=0.002; OS: HR, 0.98; 95% CI, 0.97 to 0.99; p=0.011), tumor size (DFS: HR, 1.11; 95% CI, 1.06 to 1.15; p\<0.001; OS: HR, 1.10; 95% CI, 1.05 to 1.15; p\<0.001), tumor number (DFS: HR, 1.50; 95% CI, 1.08 to 2.08; p=0.015; OS: HR, 1.49; 95% CI, 1.05 to 2.10; p=0.024), GVI (DFS: HR, 1.56; 95% CI, 1.15 to 2.11; p=0.004; OS: HR, 1.56; 95% CI, 1.12 to 2.17; p=0.009) and Glisson's capsule invasion (DFS: HR, 1.80; 95% CI, 1.28 to 2.54; p=0.001; OS: HR, 1.76; 95% CI, 1.19 to 2.60; p=0.005) were the independent prognostic factors of both the DFS and OS. And the PLR was an additional independent risk factors for the OS (HR, 1.02; 95% CI, 1.01 to 1.03; p=0.041).

3. Construction and validation of the nomograms for DFS and OS
--------------------------------------------------------------

The nomograms used to predict the DFS and OS were constructed based on above mentioned independent risk factors. For the DFS ([Fig. 2A](#f2-gnl-13-669){ref-type="fig"}), the elements of nomogram contained two continuous variables (age and tumor size) and three categorical variables (GVI, Glisson's capsule invasion, and tumor number). Younger age, larger tumor size, multiple tumor numbers, presence of GVI or Glisson's capsule invasion were considered as risk factors of lower DFS rate. The bootstrap-corrected C-index of DFS nomograms in training and validation cohorts were 0.712 (95% CI, 0.679 to 0.745; p\<0.001) and 0.704 (95% CI, 0.650 to 0.708; p\<0.001) respectively. With regard to OS ([Fig. 2B](#f2-gnl-13-669){ref-type="fig"}), the nomogram contained three continuous variables (tumor size, age, and PLR) and three categorical variables (GVI, Glisson's capsule invasion, and tumor number). The bootstrap-corrected C-index of OS nomograms in training and validation cohorts were 0.698 (95% CI, 0.657 to 0.739; p\<0.001) and 0.673 (95% CI, 0.607 to 0.739; p\<0.001) respectively. The calibration curves of both training and validation cohorts showed optimal agreement between the actual observation and nomogram-predicted probability of DFS ([Fig. 3A--F](#f3-gnl-13-669){ref-type="fig"}) and OS ([Fig. 3G--L](#f3-gnl-13-669){ref-type="fig"}) at 1, 2 and 3-year after surgery. These results suggested that these nomograms had satisfactory application value for prognostic prediction of the HCC patients with MVI after liver resection.

For clinical use of these models, the number of points for each factor was determined by drawing a vertical line toward to the point scale. For the continuous variables (age and tumor size), the number of points was equal to the nearest integer value on the point scale. Then each patient received unique DFS and OS scores by adding the points for all variables in predicted models. The projection of the total points on the survival axes indicated the estimated probability of DFS and OS at 1, 2 and 3 years, respectively.

4. Comparison of the performance between the novel nomograms and conventional staging systems
---------------------------------------------------------------------------------------------

In this study, the predictive accuracy of six conventional stage systems (Barcelona Clinic Liver Cancer \[BCLC\], American Joint Committee on Cancer \[AJCC\], Cancer of the Liver Italian Program \[CLIP\], Japan Integrated Staging Score \[JIS\], Okuda, and Hong Kong Liver Cancer prognostic classification scheme \[HKLC\]) were also calculated ([Table 3](#t3-gnl-13-669){ref-type="table"}). Overall, most of them had acceptable ability in predicting the prognosis of HCC patients with MVI with the p-value less than 0.05. However, the C-indices were significantly lower than those of present nomograms. In the training cohort, the C-indices of the nomograms for the DFS and OS were 0.712 and 0.698 respectively, which were significantly higher than those of the BCLC (DFS: 0.595, p\<0.001; OS: 0.589, p\<0.001), AJCC seventh (DFS: 0.599, p\<0.001; OS: 0.590, p\<0.001), CLIP (DFS: 0.653, p=0.005; OS: 0.655, p=0.047), JIS (DFS: 0.588, p\<0.001; OS: 0.590, p\<0.001), Okuda (DFS: 0.564, p\<0.001; OS: 0.578, p\<0.001) and HKLC (DFS: 0.599, p\<0.001; OS: 0.595, p\<0.001). In the validation cohort, the C-indices of the nomograms for the DFS and OS were 0.704 and 0.673 respectively, which were also significantly higher than those of the BCLC (DFS: 0.610, p\<0.001; OS: 0.585, p\<0.001), AJCC seventh (DFS: 0.604, p\<0.001; OS: 0.565, p\<0.001), CLIP (DFS: 0.620, p=0.02; OS: 0.618, p=0.025), JIS (DFS: 0.604, p\<0.001; OS: 0.579, p\<0.001), Okuda (DFS: 0.564, p\<0.001; OS: 0.549, p\<0.001), and HKLC (DFS: 0.623, p\<0.001; OS: 0.613, p\<0.001).

5. Comparison of the discrimination ability between the novel nomograms and conventional staging systems
--------------------------------------------------------------------------------------------------------

Using above two nomograms, the total number of points of each patient was calculated. For DFS, the total number of points of each patient ranged from 4 to 19. Then all patients were divided into four subgroups based on an interval of number of points of 4 (4--7, 8--11, 12--15, and 16--19). As shown in [Fig. 4A](#f4-gnl-13-669){ref-type="fig"}, each risk group had a distinct rate of DFS (p\<0.001). In terms of OS, the total number of points of each patient ranged from 5 to 23. Similarly, all patients were stratified into four subgroups based on an interval of number of points of 5 (5--9, 10--14, 15--19, and 20--23), each risk group also had a distinct rate of OS (p\<0.001) ([Fig. 4B](#f4-gnl-13-669){ref-type="fig"}).

Additionally, the survival curves of DFS and OS for all eligible patients were depicted by six widely used staging systems of HCC (BCLC, AJCC, CLIP, JIS, Okuda, and HKLC) ([Fig. 5](#f5-gnl-13-669){ref-type="fig"}). Compared with the survival curves derived from present nomograms, only Okuda system could stratify patients into two risk groups ([Fig. 5E, H](#f5-gnl-13-669){ref-type="fig"}); BCLC ([Fig. 5A, G](#f5-gnl-13-669){ref-type="fig"}) and HKLC ([Fig. 5F, L](#f5-gnl-13-669){ref-type="fig"}) systems were unsatisfactory in stratifying patients between stages II and III for DFS; AJCC seventh ([Fig. 5B, H](#f5-gnl-13-669){ref-type="fig"}) was unsatisfactory in stratifying patients over stage II; the CLIP score system ([Fig. 5C, I](#f5-gnl-13-669){ref-type="fig"}) was unsatisfactory in stratifying patients between 0 and 1 as well as between 3 and 4; JIS score system ([Fig. 5D, J](#f5-gnl-13-669){ref-type="fig"}) was unsatisfactory in stratifying patients between 0 and 1 as well as between 3 and 4. Taken together, the present novel nomograms had more satisfactory discrimination ability than conventional staging systems.

DISCUSSION
==========

To the best of our knowledge, we reported the largest sample size of HCC patients with MVI. The participants in the present study were distributed in different disease stages and had heterogeneous clinical characteristics, so satisfactory representative of this cohort was considered. Meanwhile, approximately 40 clinical parameters of each candidate were collected, which was expected to identify more prognosis-related variables. Via univariate and multivariate analyses, five DFS related and six OS related risk factors were finally identified. Then these independent factors were integrated and two prognosis nomograms for DFS and OS were constructed. Compared with six conventional staging systems, these novel predictive models had significantly higher prediction accuracy with C-indices of 0.712 and 0.698 for DFS and OS in training cohort respectively, and 0.704 and 0.673 for DFS and OS in validation cohort respectively. Furthermore, the Kaplan-Meier curves also showed these novel nomograms had more satisfactory discrimination ability than conventional staging systems for stratifying the prognosis of HCC patients with MVI. These results indicated that the present nomograms were convenient and powerful for predicting the prognostic outcomes of patients with MVI, and they may be helpful for guiding surgeons to plan personalized surveillance strategies and design adjuvant therapies after surgery for this subset of HCC patients.

Compared with multiple conventional staging systems, besides tumor size,[@b26-gnl-13-669]--[@b30-gnl-13-669] tumor number[@b28-gnl-13-669],[@b30-gnl-13-669]--[@b32-gnl-13-669] and GVI[@b28-gnl-13-669],[@b29-gnl-13-669],[@b33-gnl-13-669] which were well-known risk factors of HCC, some novel risk factors including age, and Glissons's capsule invasion were identified to be associated with both the DFS and OS of HCC patients with MVI, and PLR was an additional risk factor for OS in this study. To quantify the risk level of age and PLR more precisely, we expressed these two parameters as continuous variables. As shown in [Fig. 2](#f2-gnl-13-669){ref-type="fig"}, the risk points were gradually elevated with age. This results were consistent with some previous studies.[@b34-gnl-13-669]--[@b37-gnl-13-669] They found that elderly patients normally had significantly lower positivity rate of HBsAg, lower level of AFP and less advanced tumor characteristics when compared with younger patients. Therefore, a comparable or even longer median survival time was observed in elderly patients. Furthermore, the underlying mechanism on the correlation between the age and the carcinogenesis and progression of HCC were also investigated by previous studies.[@b38-gnl-13-669],[@b39-gnl-13-669] A gene analysis which was conducted by Yan *et al*.[@b39-gnl-13-669] compared the genotype and integration patterns of HBV in early- and late-onset HCC. This novel study revealed that HBV B2 serving as a risk factor of early-onset HCC is predominantly present in younger HCC patients. The HBV integration into 8q24 frequently occurs in younger patients, which effectively induced the over-expression of three well-demonstrated oncogenes (c-MYC, PVT1, and microRNA-1204)[@b40-gnl-13-669]--[@b42-gnl-13-669] in HCC tumor tissues.

Glisson's capsule is defined as the connective collagenous layer surrounding the liver parenchyma.[@b43-gnl-13-669] Glisson's capsule invasion is considered that the tumor cells invaded into but not penetrated the Glisson's capsule on microscopy. Previous studies have reported that the elasticity, thickness and texture of Glisson's capsule were associated with the stage of liver fibrosis.[@b43-gnl-13-669],[@b44-gnl-13-669] However, to our knowledge, the clinical significance of Glisson's capsule invasion in predicting the prognosis of HCC have not been reported. In this study, we identified that Glisson's capsule invasion is a novel independent risk factor of both DFS (HR, 1.80; 95% CI, 1.28 to 2.54; p=0.001) and OS (HR, 1.76; 95% CI, 1.19 to 2.60; p=0.005). In the training cohort, Glisson's capsule invasion promoted the C-indices of DFS from 0.695 to 0.712, and promoted the C-indices of OS from 0.688 to 0.698. And in the validation cohort, Glisson's capsule invasion promoted the C-indices of DFS from 0.672 to 0.704, and promoted the C-indices of OS from 0.662 to 0.673. Actually, the clinical value of organ capsule invasion has been identified and incorporated into the TNM staging system in multiple solid tumors. In thymoma, tumor invading the capsule was treated as an essential evidence for advanced stage[@b45-gnl-13-669] and an indicator of long term surveillance.[@b46-gnl-13-669] In thyroid cancer, the microscopic invasion of the thyroid capsule was defined as tumor penetration into the thyroid capsule without attachment to the surrounding muscular components,[@b47-gnl-13-669],[@b48-gnl-13-669] which was associated with poor tumor size, frequent vascular invasion[@b49-gnl-13-669] and unfavorable prognosis.[@b50-gnl-13-669],[@b51-gnl-13-669] In lung cancer, visceral pleural invasion was an independent risk factor of prognosis in each stage of TNM system.[@b52-gnl-13-669],[@b53-gnl-13-669] Therefore, the clinical significance of Glisson's capsule invasion in HCC patients without MVI and corresponding mechanisms need to be further investigated.

Recently, accumulating evidence have demonstrated that the aberrantly expressed inflammatory biomarkers prior to surgery such as PLR, NLR, C-reactive protein were prognostic factors in various solid tumors.[@b54-gnl-13-669]--[@b58-gnl-13-669] In this study, we also identified that PLR is independently associated with the OS of patients with MVI (HR, 1.02; 95% CI, 1.01 to 1.03; p=0.041). Multiple studies have investigated the underlying mechanisms of PLR in the recurrence and metastasis of HCC. The relatively overexpressed platelets produced high levels of multiple tumor-related molecules such as vascular endothelial growth factor, platelet-derived growth factor and platelet-derived serotonin,[@b59-gnl-13-669]--[@b61-gnl-13-669] which were closely correlated with the proliferation, migration and angiogenesis of HCC *in vivo* and *in vitro*. Furthermore, platelets could protect free tumor cells from immune system in the circulating system, resulting in higher possibility of intra- and/or extrahepatic metastasis.[@b62-gnl-13-669] Additionally, the patients with high levels of PLR normally accompanied with lower level of lymphocytes. Investigators have reported that low level of lymphocytic infiltration in tumor tissues was a poor prognostic factor of colorectal and HCC.[@b63-gnl-13-669]

Some limitations of this study need to be noted. Firstly, future external validations are necessary as the results of this study were calculated using the data from a single institution. Secondly, although the predicted models did not include virus-related variables such as HBV-DNA load and HBeAg, its application value for other etiologies related to HCCs needs to be further validated owing to the fact that patients in this study had underlying HBV infections. Thirdly, these nomograms only could be used to estimate the prognosis of patients with MVI after surgery; it is necessary to combine with preoperative MVI prediction models[@b11-gnl-13-669],[@b16-gnl-13-669] to manage this subset of patients as good as possible. Finally, as these nomograms were established only based on the clinical factors, other prognosis-related biomarkers need to be identified and incorporated to further promote the accuracy of these nomograms.

In conclusion, this study identified younger age, larger tumor size, multiple tumor number, GVI and Glisson's capsule invasion were the independent prognostic factors of both the DFS and OS for HCC patients with MVI following liver resection. Higher PLR was another risk factor of the OS. Two novel predictive nomograms based on these risk factors achieved more satisfactory accuracy and discrimination ability than conventional staging systems. These nomograms may be valuable in determination of individualized surveillance and adjuvant therapy for HCC patients with MVI after surgery.
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![Kaplan-Meier estimates of the prognosis of hepatocellular carcinoma patients with microvascular invasion. (A) Disease-free survival. (B) Overall survival.](gnl-13-669f1){#f1-gnl-13-669}

![Nomograms for predicting disease-free survival (DFS) and overall survival (OS) in hepatocellular carcinoma patients with microvascular invasion. (A) DFS. (B) OS.\
GVI, gross vascular invasion; PLR, platelet-to-lymphocyte ratio.](gnl-13-669f2){#f2-gnl-13-669}

![Calibration curves for predicting disease-free survival (DFS) and overall survival (OS) using the nomograms. (A--C) 1, 2, and 3-year DFS in the training cohort; (D--F) 1, 2, and 3-year DFS in the validation cohort; (G--I) 1, 2, and 3-year OS in the training cohort; (J--L) 1, 2, and 3-year OS in the validation cohort.](gnl-13-669f3){#f3-gnl-13-669}

![Kaplan-Meier estimates of the prognosis of patients according to the number of points generated using the nomograms. (A) The rates of disease-free survival (DFS) in the four risk groups were significantly different. (B) The rates of overall survival (OS) in the four risk groups were significantly different. Note: The total number of points for each patient was calculated from the nomogram plots in [Fig. 2](#f2-gnl-13-669){ref-type="fig"}. Then, the patients were divided into four risk subgroups based on 4-point (DFS) or 5-point (OS) intervals.](gnl-13-669f4){#f4-gnl-13-669}

![Kaplan-Meier estimates of the prognosis of all included patients using conventional hepatocellular carcinoma staging systems. Disease-free survival (DFS) estimated by the Barcelona Clinic Liver Cancer (BCLC) staging system (A), the American Joint Committee on Cancer (AJCC) 2010 edition (B), the Cancer of the Liver Italian Program (CLIP) staging system (C), the Japan Integrated Staging Score (JIS) (D), the Okuda staging system (E), and the Hong Kong Liver Cancer (HKLC) prognostic classification scheme (F). Overall survival (OS) estimated by the BCLC staging system (G), the AJCC 2010 edition (H), the CLIP staging system (I), the JIS (J), the Okuda staging system (K), and the HKLC prognostic classification scheme (L).](gnl-13-669f5){#f5-gnl-13-669}

###### 

The Basic Clinical Characteristics of Patients

  Clinical parameter                   Total (n=385)   Training cohort (n=255)   Validation cohort (n=130)
  ------------------------------------ --------------- ------------------------- ---------------------------
  Sex, male/female                     339/46          222/33                    117/13
  Age, yr                              50.1±12.5       49.8±12.4                 50.5±12.7
  Diabetes, yes/no                     18/367          10/245                    8/122
  HBsAg, positive/negative             342/43          223/32                    119/11
  HBeAg, positive/negative             71/314          53/202                    17/113
  Anti-HCV, positive/negative          3/382           2/253                     1/129
  HBV-DNA, \>10^3^/\<10^3^ copies/mL   178/207         117/138                   61/69
  AFP, ≤20/20--400/\>400 ng/mL         85/74/226       50/53/152                 35/21/74
  CA19-9, U/mL                         30.5±57.4       32.3±54.5                 27.1±62.5
  CA-125, U/mL                         25.9±31.5       28.3±36.6                 21.6±18.4
  CEA, ng/mL                           8.74±25.4       7.41±15.1                 11.3±38.1
  WBC, 10^9^/L                         6.0±2.6         5.9±2.6                   6.1±2.4
  NEU, 10^9^/L                         4.0±2.4         3.9±2.4                   4.0±2.4
  LYM, 10^9^/L                         1.4±0.6         1.4±0.6                   1.5±0.6
  NLR                                  3.3±3.2         3.3±3.0                   3.3±3.7
  RBC, 10^12^/L                        4.8±0.8         4.7±0.8                   4.8±0.8
  HGB, g/L                             142.3±19.8      141.7±20.5                143.4±18.5
  PLT, 10^9^/L                         155.0±77.1      152.6±72.7                159.6±85.1
  PLR                                  127.8±114.1     125.8±83.4                131.7±158.3
  PT, sec                              12.3±1.24       12.3±1.2                  12.3±1.3
  INR                                  1.1±0.4         1.1±0.5                   1.1±0.1
  TBIL, μmol/L                         20.9±63.8       17.5±29.8                 27.7±101.6
  ALB, g/L                             41.0±5.3        41±5.4                    41±5.0
  AST, IU/L                            65.0±65.1       62.8±57.1                 69.3±78.6
  ALT, IU/L                            61.0±63.1       58.2±58.6                 66.5±71.0
  GGT, IU/L                            139.5±141.8     149.1±152.6               120.5±116.0
  Child-Pugh, A/B                      361/24          239/16                    122/8
  Size, cm                             8.0±3.7         8.1/3.8                   7.6/3.5
  No., single/multiple                 284/101         188/67                    96/34
  GVI, yes/no                          129/256         88/167                    41/89
  Tumor capsule, complete/infiltrate   133/252         76/179                    57/73
  BCLC stage, A/B/C                    64/197/124      39/127/89                 21/70/39
  Anatomic resection, yes/no           234/151         166/89                    68/62
  Blood loss, mL                       582.8±759.4     562.1±524.4               622.1±1,065.2
  Transfusion, yes/no                  56/329          36/219                    20/110
  Differentiation, I+II/III+IV         175/210         115/140                   60/70
  Glisson's capsule invasion, yes/no   107/278         73/182                    34/96
  Satellite, yes/no                    79/306          49/206                    30/100
  Node metastasis, yes/no              14/371          9/246                     5/125
  Cirrhosis, yes/no                    168/217         124/131                   45/85

HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B e antigen; Anti-HCV, hepatitis C virus antibody; HBV-DNA, hepatitis B virus deoxyribonucleic acid; AFP, alpha-fetoprotein; CA19-9, carbohydrate antigen 19-9; CA-125, carbohydrate antigen 125; CEA, carcinoembryonic antigen; WBC, white blood cell; NEU, neutrophil; LYM, lymphocyte; NLR, neutrophil-lymphocyte ratio; RBC, red blood cell; HGB, hemoglobin; PLT, platelet; PLR, platelet-to-lymphocyte ratio; PT, prothrombin time; INR, international normalized ratio; TBIL, total bilirubin; ALB, albumin; AST, aspartate aminotransferase; ALT, alanine transaminase; GGT, gamma-glutamyl transpeptidase; GVI, gross vascular invasion; BCLC, Barcelona Clinic Liver Cancer staging system.

###### 

Prognostic Factors Correlated with DFS and OS Based on the Cox Proportional Hazards Model

  Clinical parameter                    DFS                 OS                            
  ------------------------------------- ------------------- --------- ------------------- ---------
  Univariate analysis                                                                     
   Sex, male/female                     0.96 (0.61--1.50)   0.85      1.20 (0.73--1.99)   0.476
   Age                                  0.68 (0.51--0.92)   0.011     0.62 (0.45--0.85)   0.003
   HBsAg, positive/negative             1.08 (0.70--1.67)   0.74      1.29 (0.78--2.14)   0.32
   HBeAg, positive/negative             1.17 (0.82--1.65)   0.387     1.34 (0.92--1.95)   0.123
   Anti-HCV, positive/negative          0.30 (0.04--2.17)   0.235     0.48 (0.07--3.44)   0.466
   HBV-DNA, ≥10^3^/\<10^3^ copies/mL    1.42 (1.03--1.96)   0.035     1.87 (1.31--2.67)   0.001
   AFP, ≤400/\>400 ng/mL                1.52 (1.12--2.07)   0.007     1.41 (1.14--1.74)   0.002
   CA19-9                               0.95 (0.69--1.29)   0.738     1.10 (0.79--1.54)   0.567
   CA-125                               1.57 (0.99--2.49)   0.058     1.53 (0.94--2.50)   0.09
   CEA                                  1.06 (0.76--1.48)   0.743     1.25 (0.87--1.79)   0.235
   WBC                                  1.37 (0.93--2.03)   0.11      1.33 (0.87--2.04)   0.181
   NEU                                  1.32 (0.91--1.91)   0.142     1.86 (1.20--2.89)   0.005
   LYM                                  0.91 (0.67--1.24)   0.554     0.87 (0.63--1.22)   0.419
   NLR, ≤3/\>3                          1.54 (1.14--2.08)   0.005     1.86 (1.35--2.58)   \<0.001
   RBC                                  0.88 (0.63--1.23)   0.454     0.90 (0.62--1.29)   0.559
   HGB                                  0.88 (0.61--1.26)   0.49      0.73 (0.50--1.07)   0.104
   PLT                                  1.38 (0.99--1.94)   0.061     1.39 (0.96--2.01)   0.08
   PLR, ≤111/\>111                      1.66 (1.23--2.23)   0.001     1.74 (1.26--2.39)   0.001
   PT                                   0.94 (0.68--1.29)   0.684     0.94 (0.67--1.33)   0.734
   INR                                  0.97 (0.70--1.35)   0.856     1.01 (0.70--1.46)   0.963
   TBIL                                 0.55 (0.26--1.17)   0.118     0.83 (0.39--1.78)   0.632
   ALB                                  0.87 (0.64--1.16)   0.339     0.76 (0.55--1.04)   0.087
   AST                                  1.24 (0.91--1.69)   0.168     1.60 (1.13--2.24)   0.008
   ALT                                  1.05 (0.78--1.41)   0.736     1.21 (0.88--1.66)   0.25
   GGT                                  1.67 (1.18--2.35)   0.003     2.09 (1.42--3.10)   \<0.001
   Child-Pugh, A/B                      1.01 (0.58--1.75)   0.971     1.06 (0.62--1.83)   0.821
   Tumor size                           1.57 (1.26--1.96)   \<0.001   1.12 (1.08--1.17)   \<0.001
   Tumor number, single/multiple        1.50 (1.08--2.08)   0.015     1.47 (1.04--2.07)   0.028
   Tumor capsule, complete/infiltrate   0.77 (0.50--1.18)   0.225     0.79 (0.49--1.27)   0.335
   GVI, yes/no                          1.71 (1.27--2.32)   \<0.001   1.78 (1.28--2.46)   0.001
   BCLC stage, A/B/C                    1.50 (1.19--1.88)   \<0.001   1.57 (1.22--2.01)   \<0.001
   Anatomic resection, yes/no           1.07 (0.79--1.46)   0.652     1.37 (0.97--1.94)   0.079
   Blood loss                           1.39 (0.98--1.97)   0.064     1.79 (1.22--2.63)   0.003
   Transfusion, yes/no                  1.20 (0.77--1.86)   0.424     1.37 (0.87--2.16)   0.174
   Differentiation, I+II/III+IV         1.40 (1.04--1.89)   0.025     1.68 (1.21--2.32)   0.002
   Liver capsule invasion, yes/no       1.75 (1.24--2.46)   0.001     1.93 (1.31--2.85)   0.001
   Satellite, yes/no                    1.60 (1.12--2.29)   0.011     1.59 (1.09--2.31)   0.016
   Node metastasis, yes/no              0.92 (0.38--2.23)   0.847     1.43 (0.58--3.48)   0.435
   Cirrhosis, yes/no                    1.11 (0.80--1.54)   0.526     1.35 (0.95--1.93)   0.099
  Multivariate analysis                                                                   
   Age                                  0.98 (0.97--0.99)   0.002     0.98 (0.97--0.99)   0.011
   Tumor size                           1.11 (1.06--1.15)   \<0.001   1.10 (1.05--1.15)   \<0.001
   Tumor number, single/multiple        1.50 (1.08--2.08)   0.015     1.49 (1.05--2.10)   0.024
   GVI, yes/no                          1.56 (1.15--2.11)   0.004     1.56 (1.12--2.17)   0.009
   Glisson's capsule invasion, yes/no   1.80 (1.28--2.54)   0.001     1.76 (1.19--2.60)   0.005
   PLR                                  \-                  \-        1.02 (1.01--1.03)   0.041

DFS, disease-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B e antigen; Anti-HCV, hepatitis C virus antibody; HBV-DNA, hepatitis B virus deoxyribonucleic acid; AFP, alpha-fetoprotein; CA19-9, carbohydrate antigen 19-9; CA-125, carbohydrate antigen 125; CEA, carcinoembryonic antigen; WBC, white blood cell; NEU, neutrophil; LYM, lymphocyte; NLR, neutrophil-to-lymphocyte ratio; RBC, red blood cell; HGB, hemoglobin; PLT, platelet; PLR, platelet-to-lymphocyte ratio; PT, prothrombin time; INR, international normalized ratio; TBIL, total bilirubin; ALB, albumin; AST, aspartate aminotransferase; ALT, alanine transaminase; GGT, gamma-glutamyl transpeptidase; GVI, gross vascular invasion; BCLC, Barcelona Clinic Liver Cancer staging system.

###### 

The C-Index Values of the Novel Nomograms and Six Conventional Staging Systems

  Prognostic system   Training cohort   Validation cohort                                                                                                      
  ------------------- ----------------- ------------------- --------- ------- -------------- --------- ------- -------------- --------- ------- -------------- ---------
  Present nomogram    0.712             0.679--0.745        \<0.001   0.698   0.657--0.739   \<0.001   0.704   0.650--0.708   \<0.001   0.673   0.607--0.739   \<0.001
  CLIP score          0.653             0.614--0.692        \<0.001   0.655   0.614--0.696   \<0.001   0.620   0.554--0.686   \<0.001   0.618   0.546--0.690   0.001
  AJCC                0.599             0.566--0.632        \<0.001   0.590   0.554--0.626   \<0.001   0.604   0.542--0.666   0.001     0.565   0.499--0.631   0.053
  HKLC                0.599             0.558--0.640        \<0.001   0.595   0.553--0.637   \<0.001   0.623   0.555--0.691   \<0.001   0.613   0.546--0.680   \<0.001
  BCLC                0.595             0.552--0.638        \<0.001   0.589   0.545--0.633   \<0.001   0.610   0.549--0.671   \<0.001   0.585   0.516--0.654   0.015
  JIS score           0.588             0.547--0.629        \<0.001   0.590   0.547--0.633   \<0.001   0.604   0.542--0.666   0.001     0.579   0.512--0.646   0.021
  Okuda               0.564             0.527--0.611        \<0.001   0.578   0.535--0.621   \<0.001   0.564   0.494--0.608   0.083     0.549   0.486--0.612   0.125

C-index, concordance index; DFS, disease-free survival; OS, overall survival; CI, confidence interval; CLIP, Cancer of the Liver Italian Program; AJCC, American Joint Committee on Cancer; HKLC, the Hong Kong Liver Cancer prognostic classification scheme; BCLC, Barcelona Clinic Liver Cancer staging system; JIS, the Japan Integrated Staging Score; Okuda, Okuda staging system.

[^1]: Liangliang Xu, Lian Li, and Peng Wang contributed equally to this work as first authors.
